Pneumotox Online
v2.2
  • RSS Feed
  • Contact
  • News
  • Diagnosing DIRD
  • Browse
  • Available on AppStore Available on AppStore

The Drug-Induced Respiratory Disease Website

Philippe Camus, M.D.

Dijon, France

  • Home
  • Browse by »
  • Drugs
  • Patterns

Hydralazine

4

III.d Alveolar hemorrhage, diffuse (ANCA-positive/-related)

1
Last update : 10/09/2012
 
Search
Advanced search
Identify causative drugs
Diagnosing DIRD
1
Drug and radiation history
2
Drug singularity - Correct identification of the drug
3
Consistent timing of exposure v. onset of symptoms
4
Clinical, imaging, BAL, pathological pattern consistent with the specific drug
5
Careful exlusion of another cause
6
Remission of symptoms with removal of drug
7
Recurrence with rechallenge (rarely advisable)
8
Causality assessment
More detailed checklist

Publications

Diagnostic dilemma: drug-induced vasculitis versus systemic vasculitis.
BMJ case reports 2023 Jul 10;16; 2023 Jul 10
Hydralazine-Induced Antineutrophil Cytoplasmic Antibody (ANCA)-Associated Vasculitis: A Case Report and Literature Review.
Cureus 2022 Apr;14;e24132 2022 Apr
Hydralazine-Induced ANCA Associated Vasculitis (AAV) Presenting with Pulmonary-Renal Syndrome (PRS): A Case Report with Literature Review.
Current cardiology reviews 2021;17;182-187 2021
Successful use of rituximab for hydralazine-induced anti-neutrophil cytoplasmic antibodies-associated vasculitis.
Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia 2019;30;226-230 2019
Hydralazine induces myeloperoxidase and proteinase 3 anti-neutrophil cytoplasmic antibody vasculitis and leads to pulmonary renal syndrome.
Case reports in nephrology 2014;2014;868590 2014
Hydralazine-induced pulmonary-renal syndrome: a case report.
American journal of therapeutics 2012 Jul;19;e136-8 2012 Jul

Powered by

  • ^
  • Contact
  • Cookies
  • About